Clinical-stage cell therapy platform with landmark NEJM-published data on hypoimmune islet cell transplantation without immunosuppression in Type 1 Diabetes (UP421, 14-month durability in first patient). Cash runway to mid-2027 (~12 months), net cash floor thin (~$0.27/share). Mayo Clinic $25M strategic investment adds validation. Active securities class action from 2025 remains a governance overhang. Base FV ~$5.50 (+65% vs $3.33); highly binary — either partnership-driven re-rating to $10+ or dilution/setback path to $1.50.
Risk-adjusted NPV sum-of-parts. Peak sales assumptions: T1D ~$30B TAM, insulin-independence therapy targeting 10-15% share = $3B upside (UP421). PoS 20% assumes clinical replication at scale is the main hurdle (regulatory path already opened). Discount rate 12%. Cross-check via EV/future-revenue at $5.80/sh confirms range. Sensitivity to UP421 PoS is extreme (±10pp ≈ ±40% FV). Base FV differs 35% from analyst consensus $8.43 because we apply heavier dilution + litigation discount that some sell-side models ignore. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| UP421 (T1D islet, hypoimmune) | $3.0B peak sales × 20% PoS × 3.0x NPV multiple / 299M shares | +6.02 |
| SC451 (iPSC-derived islet, T1D) | $2.5B peak sales × 8% PoS (pre-IND) × 2.5x NPV / 299M | +1.67 |
| SG293 (CD8 fusosome CAR T, NHL) | $800M peak × 12% PoS × 2.0x NPV / 299M | +0.64 |
| Platform optionality (autoimmune, in vivo) | 15% probability × $600M platform NPV / 299M | +0.30 |
| Net cash floor | ($160.5M cash − $80.9M debt) / 299M shares | +0.27 |
| Expected dilution (next raise) | 25% dilution haircut for $150-200M raise in next 6-12 mo at ~$3-4/sh | −2.10 |
| Litigation & governance discount | Class action reserve $50M + governance discount / 299M | −0.60 |
| Sub-total (arithmetic) | +6.02 +1.67 +0.64 +0.30 +0.27 −2.10 −0.60 = 6.20; rounded conservatively | +6.20 |
| FV base case | Applied additional 11% haircut for execution/timing risk vs mechanical sum | ≈ $5.50 |
Short interest 13.9% sits at the high end of "moderate-to-high" range for clinical-stage biotech. Combined with the low float post recent raise, a positive clinical readout could produce meaningful short squeeze dynamics. Piotroski F-Score of 1 reflects the weak financial-health scoring typical of pre-revenue biotech. No confirmed material insider selling >$500K identified in trailing 12 months, though shareholder fiduciary duty investigations are ongoing (Morningstar-cited law firm inquiries, July 2026).
| Item ($M) | FY2023 | FY2024 | FY2025 | FY2026E | Guidance FY2027E |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 (pre-launch) |
| R&D expense | 274 | 198 | 128 | ~125 | 130–150 |
| G&A expense | 83 | 70 | 47 | ~45 | 45–55 |
| Net loss | −335 | −262 | −173 | ~−140 | −150 to −180 |
| Non-GAAP cash burn | −280 | −215 | −145 | ~−140 | −150 to −170 |
| Cash & equivalents (EOP) | 209 | 210 | 138 | ~90 (pre-raise) | Requires ~$150-200M raise |
| Shares outstanding (diluted, M) | 229 | 240 | 259 | ~305 | 350–380 |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 0 | 0 | 0 | 0 | 0 |
| R&D expense ($M) | 29.8 | 32.1 | 34.5 | 28.7 | 30.7 |
| Net loss ($M) | −93.8 | −46.2 | −38.5 | −49.1 | −63.6 |
| End-of-period cash ($M) | 195 | 170 | 138 | 115 | 160 |
Business model — Hypoimmune cell therapy platform
UP421 — HIP islet cells (T1D) Peak $3-5B TAM 🟢 lead asset — clinical POC Hypoimmune primary islet cells transplanted without immunosuppression. 14-month insulin production, NEJM-published (2 papers). Next: replicate in additional patients through 2026-2027. If replicable, this is a transformational therapy for insulin-dependent T1D. SC451 — iPSC-derived islet Peak $2-3B TAM 🟡 pre-IND Scalable, off-the-shelf version of UP421 using iPSC-derived cells. IND filing targeted 2026 with Phase 1/2 initiation possible late 2026. Solves the supply constraint of primary islet approach. Bigger commercial opportunity if it works. SG293 — CD8 CAR T fusosome Peak $500M-$1B TAM 🟡 pre-clinic In-vivo delivery of CD8-targeted CAR T via fusosome. Non-Hodgkin lymphoma indication. First-in-human data expected as early as 2026. Highly competitive space (Kite, BMS, Legend) but in-vivo differentiation is meaningful.
Legal, regulatory and risk analysis
SWOT analysis
- +Landmark NEJM-published clinical POC on hypoimmune islet transplantation
- +Mayo Clinic strategic equity + collaboration (scientific validation)
- +Broad platform applicable across T1D, oncology, autoimmune
- +Analyst consensus Strong Buy, $8.43 target implies +153% upside
- +Small share count (299M) limits absolute dilution burden vs peers
- −Cash runway ~12 months — capital raise almost certain
- −Active securities class action from 2025 remains governance overhang
- −UP421 clinical data from ONE patient — replication risk high
- −No revenue, no near-term commercial product
- −Piotroski F-Score of 1 — weakest financial health tier
- →Big-pharma partnership on UP421 (Vertex, Sanofi, Novo could each pay upfront $300-500M)
- →SC451 IND clearance unlocks scalable pipeline path
- →Additional NEJM readouts on multiple patients validate platform
- →Autoimmune/in-vivo optionality untapped in current valuation
- →Short squeeze potential (13.9% SI) on positive clinical print
- !Vertex VX-880 first-mover in T1D cell therapy may set standard of care first
- !Forced dilutive raise at $2-3/sh consumes >30% of equity
- !Second/third UP421 patient failure = binary reset lower
- !Class action settlement drains $30-100M from already-thin cash
- !Biotech sector risk-off (XBI drawdowns) compresses funding window
Summary by assessment area
- Active securities class action (WDWA)
- Cash runway ~12 months forces raise
- 24% share dilution over trailing 1Y
- Piotroski F-Score = 1 (weakest tier)
- UP421: N=1 patient — replication is thesis-defining
- Vertex ahead in T1D cell therapy commercialization
- Manufacturing scale-up unproven
- SC451 IND filing on schedule critical
- Two NEJM publications = top-tier validation
- Mayo Clinic $25M + collaboration deal
- Multiple binary catalysts within 12 months
- Analyst Strong Buy, $8.43 median target
Sources: Sana Biotechnology investor relations (ir.sana.com Q2 2026 8-K, FY2025 10-K); StockAnalysis.com key statistics; Stocktwits real-time quote; CNN Markets; NEJM publications on hypoimmune islet cells (2 papers, 2026); BioSpace/GlobeNewswire pipeline updates; Kessler Topaz Meltzer & Check class action case filing (Case 2:25-cv-00512, WDWA); Morningstar shareholder investigation news; Seeking Alpha Mayo Clinic deal analysis; StockTitan Q2 2026 earnings release. Market data — last verified close 2026-09-22: SANA ~$3.33, market cap ~$997M, 52W range $2.61–$6.55, shares outstanding ~299.4M. Short interest ~13.9%. Cash $160.5M, debt $80.9M. Next earnings: Nov 5, 2026 AMC. This document is for informational purposes only and does not constitute financial or investment advice.